Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up
Massimo Federico(University of Modena and Reggio Emilia), E Damasio(Istituto di Ematologia di Bologna), L Resegotti, Teodoro Chisesi(Ospedale Civile di Venezia), Alessia Modè(Istituto di Ematologia di Bologna), Mauro Spriano(Ospedale Policlinico San Martino), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luciana Annino(Sapienza University of Rome), Marco Vinceti(Boston University), Rosangela Invernizzi(University of Pavia), Maurizio Bendandi(Universidad de Navarra), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), G. Pagnucco
Cited by 58
Related Papers
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
|PubMed|2006|909
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569